Kornimate/medical-research-clean huggingface dataset:
discussing covid-19 vaccines in private facebook groups

Conditions: COVID-19

Summary: as the covid-19 pandemic persists, a sizable proportion of the u.s. population remains unvaccinated and at high risk of death and serious illness from covid-19. vaccine hesitancy, fueled by the proliferation of vaccine misinformation on social media, is one factor contributing to lack of vaccination. current attempts to overcome vaccine misinformation focus on correcting or debunking falsehoods. although debunking strategies are important components to any public health campaign, communications must also address rationales for vaccine hesitancy that vary among individuals and communities, and directly address the gist of their concerns in an empathetic, non-judgmental manner. we will conduct a randomized controlled trial to test the effectiveness of empathic, relationship-building interactions relative to standard provision of information on social media to address covid-19 vaccine hesitancy.


Eligibility criteria:
inclusion criteria: * reside in the u.s. * unvaccinated from covid-19 * use facebook regularly (at least 1/day) exclusion criteria: * age \<18 years * do not reside in the u.s. * vaccinated from covid-19 * do not use facebook regularly (at least 1/day)

Keywords: vaccine hesitancy social media health behavior
magnetic sentinel lymph node mapping in gastric cancer

Conditions: Gastric Adenocarcinoma

Summary: this phase i finds out the possible benefits and/or side effects of using magnetic tracer ferrotrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. using ferrotrace in combination with the indocyanine green dye may help researchers better detect the disease.

primary objective: i. to assess safety by assessing short term toxicity associated with the gastric injection of the novel magnetic tracer. secondary objectives: i. to determine the feasibility of sentinel lymph node (sln) imaging and mapping using novel magnetic nanoparticles (iron conjugated polymers in saline suspension \[ferrotrace\]) for gastric cancer, and to determine whether pre-operative injection, intra-operative injection, or both are feasible. ii. to test the validity of this procedure by correlating sentinel lymph nodes (sln) to predict pathologic lymph node (ln)-positive status i.e., will a negative sln accurately predict the negativity of the other lns? iii. to determine the diagnostic value of additional hematoxylin and eosin (h\&e) sections and immunohistochemistry to assess sentinel lymph nodes compared to routine assessment with one h\&e stain alone. outline: patients are assigned to 1 of 2 cohorts. cohort i (preoperative injection): patients receive ferrotrace peritumorally within days 1-21. patients then undergo gastrectomy and receive indocyanine green (icg) peritumorally. cohort ii (intraoperative injection): patients undergo gastrectomy and receive ferrotrace and icg peritumorally during surgery.

Eligibility criteria:
inclusion criteria: * age 18 or older * willing to provide informed consent * biopsy proven gastric cancer, undergoing curative-intent gastrectomy * no distant metastases * pathologic diagnosis of gastric adenocarcinoma * pre-treatment endoscopic measurement of less than or equal to 4 cm in diameter of the gastric cancer exclusion criteria: * contraindications to surgery +/- adjuvant therapy * allergy or intolerance to iron oxide compounds * allergy or intolerance to iodides * iron overload disorder * pregnant or lactating women\* * use of contraception is required for females during the study. male patients who are sexually active with a female of childbearing potential are allowed for study enrollment and will not require use of contraception
the danish version of the surgical fear questionnaire

Conditions: Fear Anxiety; Validation

Summary: the aim of this translation and validation study is to make the the dutch surgical fear questionnaire (sfq) applicable in adult danish speaking patients referred to surgery. after succesful translation of the sfq, 200 adult patients referred to surgery at gødstrup hospital will be invited to answer the sfq as well as two other questionnaires for the validation: the pain catastrophizing scale (pcs) and the hospital anxiety and depression scale (hads). statistical analysis will be performed to assess the correlation between the scales and thus the validity of the sfq.

some of the instruments for assessing surgical fear are the amsterdam preoperative anxiety and information scale (apais), the hospital anxiety and depression scale (hads), the state-trait anxiety inventory (stai) and the visual analog scale assessing anxiety (vas-a). however, hads, stai and vas-a ask questions not particular related to perioperative procedures and thus seem too generic and apais seems unspecific despite questions directly related to anaesthesia and the surgical procedure. the dutch surgical fear questionnaire (sfq) was developed to be suitable for general use among all types of adult surgery patients to assess self-reported surgical fear, and to cover a broad range of short-term and long-term surgery-related fears. the translation and validation follows the standardized multistep process outlined by cha, kim, and erlen: 1) forward translation, 2) backward translation by native speakers, 3) a test of the translation in a pilot population of adults referred to surgery at gødstrup hospital, and 4) validation in a clinical population. for the validation of quantitatively measured clinical variables (clinimetric validation), convergent validity will be assessed between sfq, the pain catastrophizing scale (pcs) and the anxiety subscale of the hospital anxiety and depression scale (hads-a). the cronbach's alpha test will be employed to assess the internal consistency of the sfq subscales and the overall score. approval of the study has been obtained from the institutional review board at central denmark region. informed consent will be obtained from all participants prior to inclusion.

Eligibility criteria:
inclusion criteria: * 18 years or older * able to read and understand danish * cognitive well-functioning * no previously or ongoing diagnosed mental disorders * consent to participate in the study. exclusion criteria: * any patient who in the opinion of the investigator does not comply with the inclusion criteria
detection in tandem endocuff cap trial

Conditions: Colonic Neoplasms; Adenomas Serrated; Colo-rectal Cancer; Colon Adenoma

Summary: a randomised back to back study comparing cap and endocuff to detect adenomas during colonoscopy


Eligibility criteria:
inclusion criteria: 1. age 18 years and over 2. referral for surveillance, or diagnostic colonoscopy 3. ability to give informed consent exclusion criteria: 1. absolute contraindications to colonoscopy 2. established or suspicion of large bowel obstruction or pseudo-obstruction 3. known colon cancer or polyposis syndromes 4. known colonic strictures 5. known severe diverticular segment (that is likely to impede colonoscope passage) 6. patients with active colitis (ulcerative colitis, crohn's colitis, diverticulitis, infective colitis) 7. patients lacking capacity to give informed consent 8. pregnancy 9. patients who are on clopidogrel, warfarin, or other new generation anticoagulants who have not stopped this for the procedure

Keywords: colonic adenoma serrated polyps caecal intubation time withdrawal time polyp miss rate
mapping the endocrine determinants of ovarian stimulation to optimize outcomes in fresh embryo transfer cycles

Conditions: Infertility

Summary: the goal of this project is to identify autocrine, paracrine and endocrine factors which are associated with intercycle variation in cyclical follicle recruitment. patients will be monitored in a natural cycle, a stimulated cycle and a follow up. in the stimulated cycle patients will be randomized to co-treatment with aromatase inhibitor or placebo during ovarian stimulation.

the primary aim of this project is to explore the putative cyclic recruitment 'gatekeeping' functions of gonadotropins, sex steroids, anti-muellarian hormone and pregnancy associated plasma protein a in normal ovulatory cycles, and the impact of ovarian stimulation on cyclic follicle recruitment in the following cycle. it is further proposed that supra-physiological levels of estradiol and progesterone which arise from ovarian stimulation may modulate the size of the secondarily recruited follicle cohort in the next cycle. in order to explore the relative contribution of sex steroids as determinants of the size of the next cycle 'wave' of recruitment further, a second aim of this study will be investigate whether limiting the rise in sex steroid levels during ovarian stimulation, by co-treatment with aromatase inhibitor impacts on cyclic recruitment.

Eligibility criteria:
inclusion criteria: * indication for ivf/icsi treatment * eligible for ivf/icsi treatment according to local criteria * regular cycles 21-35 days (both included) * age \<40 years * amh 8-32 (both included) * written consent * willing to undergo intensive monitoring in a natural cycle (the cycle prior to the monitored natural cycle must be hormone treatment free), stimulated cycle and follow up in the subsequent cycle exclusion criteria: * any contraindication for ivf/icsi treatment according to local criteria * previous stimulation for ivf/icsi with \< 4 oocytes obtained * pcos * undergoing ivf/icsi for the purpose of fertility preservation * allergy towards study drug
a randomized study to assess the safety of grf6019 infusions in subjects with mild to moderate alzheimer's disease

Conditions: Alzheimer Disease; Mild to Moderate Alzheimer Disease

Summary: this study is evaluating the safety, tolerability, and feasibility of grf6019, a plasma-derived product, administered as an intravenous (iv) infusion, to subjects with mild to moderate alzheimer's disease.

this is a randomized, double-blind, dose-comparison concurrent control study to assess the safety, tolerability, and feasibility of grf6019, a plasma-derived product, administered by intravenous (iv) infusion to subjects with mild to moderate alzheimer's disease. subjects will be randomized 1:1 to a low dose or a high dose of active treatment in a double-blind manner. all subjects will receive one infusion per day at the randomized dose for 5 consecutive days during week 1 and, again, during week 13 (for a total of 10 doses per subject). all iv infusions will take place at an inpatient research unit while the follow-up visits after each treatment period will be on an outpatient basis. subjects will participate for a total of 6 months in this study.

Eligibility criteria:
inclusion criteria: * diagnosis of probable ad based upon the national institute on aging-alzheimer's association (nia-aa) criteria * mmse score 12-24 inclusive * modified hachinski ischemia scale (mhis) score of ≤ 4 * provided a signed and dated informed consent form (either the subject and/or subject's legal representative as well as the trial partner) exclusion criteria: * evidence of clinically relevant neurological disorder(s) other than probable ad * history of blood coagulation disorders or hypercoagulability; any concurrent use of an anticoagulant therapy. (e.g., heparin, warfarin, thrombin inhibitors, factor xa inhibitors). use of antiplatelet drugs (e.g., aspirin or clopidogrel) is acceptable. * initiation or change in the dosage of cholinesterase inhibitors (achei), memantine, axona, vitamin e supplementation or selegiline within 3 months prior to screening. * heart disease (or history thereof), as evidenced by myocardial infarction, unstable, new onset or severe angina, or congestive heart failure (new york association class ii, iii or iv) in the 6 months prior to dosing; uncontrolled high blood pressure (systolic blood pressure of 160 mmhg or higher and/or diastolic blood * prior hypersensitivity reaction to any human blood product or intravenous infusion; any known clinically significant drug allergy. * treatment with any human blood product, including transfusions and intravenous immunoglobulin, during the 6 months prior to screening. * history of immunoglobulin a (iga), haptoglobulin or c1 inhibitor deficiency; stroke, anaphylaxis, or thromboembolic complications of intravenous immunoglobulins. * hemoglobin \<10 g/dl in women; and \<11 g/dl in men.
study comparing two strategies of exercise in breast and colon cancer survivors and their impact on fatigue

Conditions: Neoplasms; Fatigue

Summary: breast and colon cancer survivors with no evidence of disease, who score less than 45 in the predict questionnaire for fatigue, will be randomized to a supervised strength program versus a supervised resistance program. the primary objective is improvement of cancer-related fatigue.

patients should have finalized their oncological treatment in the previous 5 years. the sample size (32 patients) was calculated to improve the perception of fatigue score from an anticipated initial 38 to a post-intervention 48. the control arm consist of supervised strength training in two sessions per week with non-supervised international recommendations for aerobic exercise. the experimental arm will consist of supervised strength + resistance training in two sessions per week. after evaluating the weekly physical activity through accelerometer, body composition through dexa and the cardiorespiratory fitness through cpet, participants will initiate the training according to a randomized assignment. secondary objectives include: 1. cardiorespiratory fitness, 2. quality of life; 3. adherence to the training program; 4. adherence to international recommendations, 5. body composition, 6. employment status

Eligibility criteria:
inclusion criteria: * 18-65 * history of breast or colon cancer * no evidence of disease * end of treatment in the last five years * able to understand the questionnaire perform * able to manage the accelerometer exclusion criteria: * mobility limitation * treatment with beta-blockers * exclusion criteria for cpet

Keywords: cancer survivors training exercise cancer-related fatigue
hydroxyurea treatment for adult sickle cell anemia patients in kinshasa

Conditions: Sickle-Cell Anaemia

Summary: the goal of this clinical trial is to evaluate the efficacy of hydroxyurea (hu) in improving disease severity in adult patients with sickle cell anemia in kinshasa (democratic republic of congo). this study aims to: * assess the safety and efficacy of hu treatment in the congolese environment; * assess the reversibility of chronic cardiac lesions. participants will take hydroxyurea for two years. the effects of the treatment will be evaluated periodically by clinical evaluation, biological tests, and echocardiographic exploration.

sickle cell disease is common in sub-saharan africa, particularly in the democratic republic of the congo (drc). it is characterized by chronic hemolytic anemia with the need for transfusions, painful osteoarticular crises, and chronic organ damage, including the heart. hydroxyurea (hu) is a drug widely used in sickle cell patients in wealthy countries, while it is little used in poor countries with a high incidence of the disease. this prospective study will focus on homozygous sickle cell participants, naïve to hu treatment. participants will take hu in gradually increasing doses. they will be monitored for the possible occurrence of side effects. the effectiveness of the treatment will be evaluated according to the reduction in painful crises, and the need for blood transfusion; as well as based on biological changes and the reversibility or stabilization of cardiovascular complications.

Eligibility criteria:
inclusion criteria: * sickle cell anemia confirmed by dna testing; * moderate to severe clinical severity of sickle cell anemia; * fetal hemoglobin lower than 15%. exclusion criteria: * poor compliance to follow-up consultation during the observational year * participant already treated with hu * pregnant women * breastfeeding women * congenital heart disease * pulmonary disease

Keywords: sickle cell anemia hydroxyurea adult patients kinshasa
health-related qol following tavi tao, tavi tf and avr

Conditions: Quality of Life

Summary: the aim of the study was to evaluate short- and long-term changes in qol in patients undergoing tavi and to assess differences in patient qol when using the tavi tao approach compared with the transfemoral approach (tavi tf) and surgical aortic valve replacement (savr).


Eligibility criteria:
inclusion criteria: * aortic valve stenosis exclusion criteria: -

Keywords: tavi quality of life savr
development of a biomarker directed strategy to ameliorate common toxicities from conventional chemotherapy

Conditions: Lymphoma; Sarcoma

Summary: side effects from chemotherapy can be severe in some patients leading to admission to hospital, a worse quality of life and delays in subsequent doses of chemotherapy. a blood test that could predict patients who will go on to develop severe side effects could be useful and might allow early intervention with medicines to reduce the severity of the symptoms and prevent admission to hospital. this study will collect blood samples from patients with lymphoma or sarcoma who are receiving chemotherapy (with an expected admission rate for neutropenic sepsis, one of the side effects that most commonly results in hospital admission, of less than 20%). it will assess whether changes in blood proteins ("biomarkers") taken 2 days after the 1st chemotherapy can predict subsequent severe side effects throughout the 4 months of chemotherapy. in addition the investigators will collect data on quality of life and contact with medical professionals to assess the costs of chemotherapy toxicity to both the patient and health service. this will allow us in the future to model the cost effectiveness of using biomarkers in this manner to try and reduce chemotherapy toxicity.


Eligibility criteria:
inclusion criteria: * patients with lymphoma or sarcoma identified to receive out-patient chemotherapy with an anticipated febrile neutropenia rate of less than 20%. this would include 21 day r-chop in patients under 70 and single agent doxorubicin \[aapro et al, 2011a\]. * age 18 or older * performance status 0-2 * before patient registration, written informed consent must be given according to ich/gcp, and national regulations. exclusion criteria: * past history of hiv, hepatitis b or c positive, due to the difficulties in handling high-risk specimens within cep. * major surgery, radiotherapy, chemotherapy or mechanism based agents within the last 4 weeks. * radio-immunotherapy within the last 8 weeks. * bilirubin greater than 1.5 x the upper limit of normal and alt greater than 2.5 x the upper limit of normal (as disturbed liver function tests are associated with elevated ck18) \[gonzalez-quintela et al, 2009, lavallard et al, 2011\] * presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
improved modified care meals to improving the quality of life of the pre-frailty chewing disorders of the older adult

Conditions: Food Selection; Quality of Life; Chewing Disease; Satisfaction

Summary: in 2020, we have entered an aging society. during the aging process, the body will decline with age, and the muscles will decrease, which will affect the swallowing muscles, causing chewing and swallowing difficulties are very common. difficulty masticating is associated with problems with real teeth, dentures, and oral health disease, and is associated with infection, pain, inadequate nutritional intake, affected appearance, decreased quality of life, and mortality. at present, taiwan mostly provides the elderly with shredded food, cooked soft and rotten food, or whipped food. however, when the food is mashed or shredded, the original color, fragrance, and taste of the food will be lost. it cannot change the appetite of the elderly, and it will reduce the satisfaction of the elderly's meal, and there will still be risks of insufficient food intake and uneven nutrition. appearance or taste can improve the satisfaction and quality of life of the elderly, improve the health needs of nutrition, and allow a variety of choices when eating to change the current situation of traditional whipped food and shredded meals.it is expected that the quality of life, nutritional status, and meal satisfaction of the pre-frail elders with masticatory difficulties will be significantly higher than those of the control group if the subjects receive care meals, which can be used as a reference for the daily care of the elderly with masticatory disorders in the future.


Eligibility criteria:
inclusion criteria: * elderly over 65 years old. * elders who are pre-frail cases after the five assessments of frailty and who are abnormal after the chewing test. * clear awareness, willing to accept visitors, able to communicate in chinese and taiwanese. * ability to express food appearance and taste. * those who eat by mouth. exclusion criteria: * elderly with dementia (certified by medical records and disability handbook). * elderly people who have swallowing disorders in the throat stage after being screened by the modified water swallowing test. * visually impaired and no primary caregiver to assist the program implementer.
role of pco2 gap as predictor of clinical outcome in icu septic patients

Conditions: Sepsis

Summary: sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, if not recognized early and managed promptly, it can lead to septic shock, multiple organ failure and death. sepsis is associated with high mortality, and the early recognition of the signs of tissue hypo perfusion is crucial in its management. this prospective study was aimed to detect that pco2 gap can be taken as a reliable prognostic tool in septic patients

in the community setting, sepsis often presents as the clinical deterioration of common and preventable infections. sepsis also frequently results from infections acquired in health care settings, which are one of the most frequent adverse events during care delivery and affect hundreds of millions of patients worldwide every year the venous-to-arterial carbon dioxide difference (pv-aco2) can indicate the adequacy of microvascular blood flow in the early phases of resuscitation in sepsis. hence, other resuscitation goals, such as pco2 gap, have been suggested, due to their ability to predict adverse clinical outcomes and simplicity in patients achieving normal oxygen-derived parameters during the early phases of resuscitation in septic shock. blood lactate level is also useful in evaluating sepsis. serum lactate is a good indicator of the presence of hypoxic tissue during septic shock, since its production takes place during anerobic metabolism. procalcitonin (pct) is the precursor of calcitonin, and higher levels are associated with the development of sepsis. com¬monly, there is an elevation of pct levels 4 h after the on¬set of symptoms, peaking between 8 h and 24 h.

Eligibility criteria:
inclusion criteria: * adult septic patients ≥ 21 years old exclusion criteria: * patients with history of chronic obstructive pulmonary disease and bronchial asthma.
descemet membrane endothelial keratoplasty (dmek)

Conditions: Corneal Dystrophies, Hereditary

Summary: to evaluate isolated descemet membrane transplantation as a refinement of previous advanced techniques for corneal transplantation, like descemet stripping endothelial keratoplasty (dsek)

see above.

Eligibility criteria:
inclusion criteria: * corneal endothelial disorders exclusion criteria: * n/a

Keywords: corneal transplantation, descemet membrane